Earnings, deals and disclosures from Japan's listed pharma & healthcare companies, in English.
Revenue rose to ¥201.68bn and pretax profit rebounded to ¥14.27bn in the year to March, but profit attributable to owners of parent slipped to ¥10.44bn and EPS eased to ¥90.39. That leaves a familiar generics-market tension: operations improved before tax, shareholders saw less of it at the bottom line.
Sales rose to ¥9.91bn and ordinary income turned positive at ¥256.4mn, while net income reached ¥227.2mn. Operating cash flow was still negative at ¥486.9mn, even as the annual dividend rose to ¥3.50 a share.
Revenue rose to ¥2,139,245,000,000 in the year to March 2026 from ¥1,912,323,000,000 a year earlier, while profit before tax jumped to ¥376,587,000,000 and net profit attributable to owners of parent to ¥291,535,000,000. ROE reached 17.4%, and a separate internal control report said financial-reporting controls were effective as of March 31.
The three months to April 30 produced no revenue and an ¥836 million net loss, yet AKUGO was added to Japan's reimbursement list in May at ¥72 million and commercial sales began. SanBio also said it agreed Phase 3 trial design with the FDA for traumatic brain injury, though the company did not disclose early sales volume or hospital uptake.
CellSource turned a softer top line into a better interim profit picture. Consolidated revenue for the six months to April slipped 2.5% to JPY 1,775m, but SG&A fell 8.5% and operating profit climbed to JPY 125m from JPY 17m, even as combined blood- and adipose-derived processing cases edged down to 10,114 from 10,303. Management still kept its full-year forecast for a JPY 170m operating loss, saying the year remains one of strategic investment rather than tidy recovery.